Medipattern's Visualize:Vascular(TM) Helps Physician Identify Patient at High Risk to Stroke

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern" or the "Company") (TSX VENTURE:MKI),
a pioneer in the development of medical imaging software solutions that help
medical practitioners to better understand lesions and critical anatomy,
announced today that the Company's new Visualize:Vascular(TM) continues to
pinpoint patients with critical problems so that the patient can receive
immediate care. 


"Visualize:Vascular correctly identified a patient as having significant luminal
reduction who would have never been identified using the 'standard of care'
carotid Doppler Ultrasound Exam. The ultrasound results indicated slightly
elevated velocities in the internal carotid artery indicative of a 50-60%
stenosis but of no immediate concern. As part of our new protocol we then
performed a 3D rendering of the same area with Visualize:Vascular. The 3D image
generated by the software showed that the patient had significant luminal
reduction which should require immediate attention. The case was discussed with
the referring physicians and a Magnetic Resonance Angiogram (MRA) was ordered
which confirmed that the patient had significant Stenosis requiring immediate
action," stated Daniel Gurell, MD, of University Diagnostic Medical Imaging
(UDMI) in Bronx, New York. "Luminal Reduction is a leading factor in determining
a patient's risk of having a stroke. It can also be phrased in terms of
Stenosis. If a patient measures 80 to 90% Stenosis on an angiogram, then surgery
is recommended. In this case the ultrasound exam results were in the 50 to 60%
range while 3D visualization and the MRA were in line with each other in the 80
to 90% range which is a huge difference, the difference between observing the
patient at the next annual exam and ordering immediate surgery. The patient is
being treated with surgery now. Being able to properly identify the patients who
are at high risk to stroke enables the medical team consisting of the patient's
cardiologist, radiologist like me and vascular surgeon to work together to
prevent catastrophic strokes. Visualize:Vascular has helped us considerably with
this patient and will aid us in our goal to prevent strokes before they happen."


"UDMI is committed to keeping abreast of the technological advances in radiology
and to incorporating them into the practice. The practice is at the fore front
of the field trying new technologies such as Medipattern's Visualize:Vascular.
UDMI was the first full-service diagnostic radiology facility in the nation to
earn all eight of the accreditations offered by the American College of
Radiology," commented Medipattern CEO, Jeff Collins. "All of us at Medipattern
are very privileged to work with Dr. Gurell and his team. We are pleased that
our product was there to help make a difference. This experience helps provide
another validation point along the way to show that our technology is capable of
making a hugely positive impact on patient care."


Upcoming Events



Annual Hospital - Physician Leadership                                      
 Conference MHA                              March 16, 2012    Waltham, MA  
Annual Meeting - MHA                         June 6 - 7, 2012  Brewster, MA 
SVU/SVS Annual Conference                    June 7 - 9, 2012  Baltimore, MD



About the Medipattern Corporation:

Medipattern(R) is a pioneer in the development of imaging software solutions
that help medical practitioners to better understand lesions and critical
anatomy. Medipattern uses its Cadenza(TM) technology to process images, finding
the salient region of interest and presenting them in 2D and 3D formats that
enhance the reader's perception. For more information, please visit the
Company's website: www.medipattern.com.


Medipattern(R) is a registered mark of The Medipattern Corporation.
Visualize:Vascular(TM) is a trademark of the Medipattern Corporation.


Forward-looking statements

This document contains forward-looking statements relating to Medipattern's
performance, operations, or business environment. These statements are based on
what we believe are reasonable assumptions given currently available information
and our understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements using words such
as "anticipates," "believes," "estimates," "expects," "plans," "intends,"
"potential," and similar expressions. Forward-looking statements are not
guarantees of future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause actual outcomes
and results to differ materially from those expressed in forward-looking
statements. These factors include but are not limited to those set forth in the
Company's corporate filings, (posted at www.sedar.com). In addition, these
forward-looking statements relate to the date on which they are made. The
Company disclaims any intention or obligation to update or revise any
forward-looking statements for any reason. Readers should not rely on
forward-looking statements.